Replies to post #83656 on NorthWest Biotherapeutics Inc (NWBO)

[iclight]

Sure. Oh yeah, when is it starting?

From the university's PR:

After completing certain preparatory activities, including obtaining regulatory approvals, the Phase II trial will treat patients for up to 6 months with DCVax®-L and the checkpoint inhibitor Pembrolizumab, followed by long-term follow-up. The effects of this combination therapy will be monitored with magnetic resonance imaging (MRI) as well as “liquid biopsy” measures.

So what, another 6 months to start, 6 months to treat, and then long term follow up. Yay!

Given it takes the company 6 months to translate a contract....